Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2026)

Aquestive Therapeutics' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $20.2 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 2.8% year-over-year to $20.2 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 2.8% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 94.81% from the prior year.
• Current Deferred Revenue advanced to $20.2 million in Q1 2026 per AQST's latest filing, from $1.1 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $37.8 million in Q1 2023 and bottomed at $774000.0 in Q3 2022.
• The 5-year median for Current Deferred Revenue is $20.2 million (2026), against an average of $13.8 million.
• Across the five-year window, Current Deferred Revenue surged 2264.23% in 2023 and sank 94.81% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.5 million in 2022, then grew by 2.51% to $1.6 million in 2023, then soared by 1257.38% to $21.1 million in 2024, then sank by 94.81% to $1.1 million in 2025, then surged by 1750.73% to $20.2 million in 2026.
• Per Business Quant, the three latest AQST Current Deferred Revenue figures stand at $20.2 million (Q1 2026), $1.1 million (Q4 2025), and $20.8 million (Q3 2025).